Physician profile
Hope Ann Steinforth
NPI 1497443394
$5,947.90
in general payments reported to CMS, 2019-2025
25 companies · $3,177 in 2025
The $3,177 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,058 · 2024: $1,712 · 2025: $3,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,357 · Education: $591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,357.03 |
| Education | $590.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,661.00 | 2023-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $941.68 | 2023-2025 | Tremfya |
| Abbvie INC. | $646.81 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $431.76 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $420.52 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $274.46 | 2023-2025 | Otezla, Otezla |
| Genzyme Corporation | $256.95 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $180.32 | 2024-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.48 | 2024-2025 | Spevigo |
| Ucb, INC. | $156.10 | 2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $127.07 | 2024 | Sotyktu |
| Leo Pharma INC. | $100.75 | 2025 | Adbry, Anzupgo |
| Almirall LLC | $88.58 | 2023-2024 | Klisyri |
| Incyte Corporation | $79.56 | 2023-2025 | Opzelura |
| Pfizer INC. | $59.81 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $59.17 | 2024-2025 | Ameluz, Rhodoled Xl, Xepi |
| Galderma Laboratories, L.P. | $57.22 | 2023-2025 | Aklief, Dysport |
| Dermavant Sciences, INC. | $44.16 | 2024 | Vtama |
| Mayne Pharma Commercial LLC | $37.52 | 2025 | |
| Novartis Pharmaceuticals Corporation | $35.15 | 2025 | |
| Springworks Therapeutics, INC. | $28.82 | 2025 | |
| Chiesi USA, INC. | $28.40 | 2025 | Filsuvez |
| Verrica Pharmaceuticals INC. | $24.69 | 2025 | Ycanth |
| Revance Therapeutics, INC. | $23.16 | 2024 | Daxxify |
| Strata Skin Sciences, INC. | $20.76 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hope Steinforth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.